EN DE

BioSmart Co (038460) Fair Value & Analysis

Technology · KR · Market cap 70.9B KRW

BC BioSmart Co 038460 · KQ
Price2,880 KRW
Fair Value9,981 KRW
Upside+246.6%
Quality42/100
Watch BioSmart Co for free, get notified when fair value or trend changes. Watch for free
Expensive Growth
Thin margins · 0.7% net margin
Low debt · negative free cash flow
Mixed vs. peers (3/6)
Narrow moat 23/100
Evidence: Medium Range 7,485 KRW – 12,476 KRW Share as image

Fair value as of: Aug 13, 2026

From 14 valuation models · updated yesterday

Fair value updated Aug 13, 2026, revised from 7,129 KRW to 9,981 KRW (+40.0%) since Jul 22, 2026. Share price +3.6% over the past month.

Below-average quality, screening 247% undervalued on our models.

What matters now

  • The large discount to fair value meets weak quality (42/100). That raises the risk this is a value trap rather than a bargain.
  • The price is below even our cautious bear case (7,485 KRW). The market is more pessimistic than our downside scenario.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

9,290 KRW 2,325 KRW Fair Value 9,981 KRW Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range 2,325 KRW – 9,290 KRW · fair‑value band 7,485 KRW – 12,476 KRW · the 2,880 KRW price screens below the 9,981 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

BioSmart Co (038460) currently trades at 2,880 KRW, while our model-based Fair Value estimate is 9,981 KRW, implying the stock looks roughly 246.6% undervalued today. The Quality Score stands at 42/100 (below-average quality), in the Technology sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, BioSmart Co generated revenue of 333B KRW at a net margin of 0.7%. Revenue grew 94.2% year over year. Net debt stands at 41.8B KRW. Fundamentals as of Aug 13, 2026

Our scenario range runs from 7,485 KRW (bear case) to 12,476 KRW (bull case); at 2,880 KRW, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 58% below its 52-week high and 11% above its 52-week low, currently below its 200-day average. For context, the median of 10 Technology peers we cover trades at 11% fair-value upside, at 247%, 038460 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Residual Income 4,524 KRW 4,690 KRW 4,824 KRW 76
ROIC Compounder 9,430 KRW 14,131 KRW 17,486 KRW 72
Growth-Adj P/E 8,023 KRW 11,461 KRW 14,899 KRW 68
All 14 models by family
Earnings-Based
Graham-Dodd 2,424 KRW 16,904 KRW 23,722 KRW 54
Lynch FV 5,207 KRW 7,439 KRW 9,671 KRW 50
PEG = 1.0 5,207 KRW 7,439 KRW 9,671 KRW 46
EPV 7,824 KRW 9,108 KRW 10,231 KRW 59
Multiples
P/E Multiple 7,485 KRW 9,981 KRW 12,476 KRW 63
P/S Multiple 4,545 KRW 6,060 KRW 7,575 KRW 58
P/B Multiple 4,545 KRW 6,060 KRW 7,575 KRW 55
EV/EBIT 16,298 KRW 21,691 KRW 27,084 KRW 53
EV/EBITDA 16,225 KRW 21,594 KRW 26,962 KRW 54
EV/Revenue 8,299 KRW 11,804 KRW 15,310 KRW 43
Asset-Based
NCAV (Graham) 2,849 KRW 3,817 KRW 5,697 KRW 50
Economic Profit
Residual Income 4,524 KRW 4,690 KRW 4,824 KRW 76
ROIC Compounder 9,430 KRW 14,131 KRW 17,486 KRW 72
Growth Earnings
Growth-Adj P/E 8,023 KRW 11,461 KRW 14,899 KRW 68

Widest divergence: Growth Earnings (11,461 KRW) versus Asset-Based (3,817 KRW). Highest evidence: Residual Income (76).

Notify me when 038460 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 333B KRW
Revenue growth (YoY) +94.2%
Net margin 0.7%
Return on equity -178%
Free cash flow −9.7B KRW FY2025
Operating margin 2.7%
More key figures
EPS growth (YoY) +171%
Net debt 41.8B KRW FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 42/100

Of which business quality 45 · Market factors (momentum, volatility) 18

Profitability 47
Margins and returns on capital today
Quality Growth 38
Are margins and returns improving?
Cashflow 35
Earnings quality: real cash, not paper profit
Fin. Strength 58
Balance sheet, leverage, solvency risk
Investment 52
Disciplined investing over empire-building
Low Volatility 23
Calm price path (market factor)
Momentum 15
Price trend over the last 3–12 months (market factor)
52W Momentum 18
Distance to the 52-week high (market factor)
Net Issuance 40
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

BioSmart Co.,Ltd. manufactures and sells magnetic stripe (MS) cards in South Korea. The company's magnetic stripe cards include credit cards, smart cards, traffic cards, securities cards, etc.

Full company description

BioSmart Co.,Ltd. manufactures and sells magnetic stripe (MS) cards in South Korea. The company's magnetic stripe cards include credit cards, smart cards, traffic cards, securities cards, etc. It also sells card equipment, such as traffic card issuing machinery, smart card issuing machinery, credit card issuing machinery, etc.; provides card issuing services comprising MS card and IC chip personalization, and photo-transferring; and develops software programs related to credit card issuing. The company was formerly known as KBC Corporation and changed its name to BioSmart Co.,Ltd. in March 2007. BioSmart Co.,Ltd. was founded in 1971 and is headquartered in Seoul, South Korea.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

BioSmart Co reported revenue of 483B KRW in FY2025 versus 189B KRW in FY2021, a compound +26.4%/yr. Reported net income was 9.0B KRW in FY2025, compounding +59.5%/yr from FY2021.

Growth Quality 52/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Latest Revenue (FY 2025)
483B KRW
Latest YoY
−0.3%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+7.2%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+23.7%
Avg. growth/yr (15Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+19.9%
Revenue +26.4%/yr
FY21 189B KRW
FY22 392B KRW
FY23 456B KRW
FY24 484B KRW
FY25 483B KRW
Net income +59.5%/yr
FY21 1.4B KRW
FY22 721M KRW
FY23 17.9B KRW
FY24 127M KRW
FY25 9.0B KRW

Watch 038460: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "BioSmart Co Fair Value". https://www.fairvalue-calculator.com/stock/038460

Peer Group

Electronic Equipment & Parts · 19 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 42 · Bottom 25%
Return on assets 3% · Above median
Net margin (TTM) 1% · Below median
Operating margin (TTM) 3% · Above median
Revenue growth 94% · Top 25%
Debt / equity 0.19× · Higher than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 21
FUTURE 100 · sector 0
PAST 0 · sector 0
HEALTH 91 · sector 100
DIVIDEND 0 · sector 0

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Electronic Equipment & Parts stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
STCube, Inc 052020 9,130 KRW 2,160 KRW -76%
VINATech Co 126340 76,700 KRW 24,754 KRW -68%
Partron Co 091700 5,860 KRW 13,133 KRW +124%
Amotech Co 052710 13,520 KRW 14,277 KRW +6%
KHVATEC Co 060720 11,770 KRW 23,424 KRW +99%
MNTech Co 095500 7,440 KRW 8,280 KRW +11%
Namuga Co 190510 14,070 KRW 44,255 KRW +215%
Powerlogics. Co 047310 3,200 KRW 5,000 KRW +56%
e-LITECOM CO., Ltd 041520 11,570 KRW 11,520 KRW -0%
Ajinextek Co 059120 7,440 KRW 3,455 KRW -54%

Compare BioSmart Co with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Technology stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is BioSmart Co (038460) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of 9,981 KRW versus a price of 2,880 KRW, about +247% (undervalued).
What is the fair value of 038460?
Our model-based fair value for BioSmart Co is 9,981 KRW (as of Aug 13, 2026), built from audited fundamentals. The current price is 2,880 KRW.
What is the quality score of 038460?
BioSmart Co has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of BioSmart Co (038460)?
BioSmart Co reported trailing-twelve-month revenue of about 333B KRW (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 038460?
The net profit margin of BioSmart Co is about 0.7%, meaning it keeps roughly 0.7% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track BioSmart Co and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.